We have just received confirmation that the Haemophilia Scotland Patient Group submission to the Scottish Medicines Consortium (SMC) in relation to ledipasvir-sofosbuvir (Harvoni) has been accepted.
We are taking part in the SMC process to make the case for a wide choice of the new, interferon-free, treatments for Hepatitis C to be made available in Scotland. If the SMC decides that a treatment is good value for money then all of the Local Health Boards in Scotland have permission to uses it. However, they still make their own decisions about what treatments they can afford to fund.
The next step for ledipasvir-sofosbuvir (Harvoni) is the SMC meeting which will make the decision. The Scottish Medicines Consortium (SMC) meetings are open to members of the public and press to observe. Although the public can’t speak at the meetings, seeing how the decisions are made can help anyone who wants to understand how evidence is assessed and interpreted – as well as how consultation comments like ours are taken into account.
The relevant meeting is on Tuesday 3rd February from 12:30pm to 4:30pm at The Lighthouse, 11 Mitchell Lane, Glasgow G1 3NU.
If you would like to attend then all you need to do is complete a very short registration form on the SMC website.